ARCUTIS BIOTHERAPEUTICS INC

NASDAQ: ARQT (Arcutis Biotherapeutics, Inc.)

Kemas kini terakhir: 3 hari lalu, 9:46PM

15.24

0.59 (4.03%)

  • 1H 4.03%
  • 5H 4.31%
  • 1B 6.57%
  • 6B 46.54%
  • Tahun Ke Tarikh 4.67%
  • 1T 93.40%
  • 5T -37.75%
Penutupan Terdahulu 14.65
Buka 14.75
Jumlah Dagangan 1,549,594
Purata Dagangan (3B) 2,470,275
Modal Pasaran 1,816,592,768
Harga / Jualan (P/S) 9.38
Harga / Buku (P/B) 11.53
Julat 52 Minggu
6.99 (-54%) — 17.75 (16%)
Tarikh Pendapatan 6 May 2025
Margin Keuntungan -71.25%
Margin Operasi (TTM) -10.69%
EPS Cair (TTM) -1.16
Pertumbuhan Hasil Suku Tahunan (YOY) 427.60%
Jumlah Hutang/Ekuiti (D/E MRQ) 70.19%
Nisbah Semasa (MRQ) 4.14
Aliran Tunai Operasi (OCF TTM) -112.16 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -73.08 M
Pulangan Atas Aset (ROA TTM) -23.25%
Pulangan Atas Ekuiti (ROE TTM) -113.76%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Bercampur Menurun
Biotechnology (Global) Bercampur Menurun
Stok Arcutis Biotherapeutics, Inc. Menaik Menaik

AISkor Stockmoo

1.0
Konsensus Penganalisis 1.5
Aktiviti Orang Dalam NA
Volatiliti Harga -4.5
Purata Bergerak Teknikal 5.0
Osilator Teknikal 2.0
Purata 1.00

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
ARQT 2 B - - 11.53
CORT 8 B - 59.16 11.43
BBIO 7 B - - -
AXSM 6 B - - 90.89
ACLX 4 B - - 7.94
RARE 4 B - - 14.33

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
Sektor Healthcare
Industri Biotechnology
Gaya Pelaburan Small Growth
% Dimiliki oleh Orang Dalam 2.01%
% Dimiliki oleh Institusi 111.60%

Pemilikan

Nama Tarikh Syer Dipegang
Suvretta Capital Management, Llc 31 Dec 2024 11,399,138
Ensign Peak Advisors, Inc 31 Dec 2024 2,374,140
69.6069.6052.8052.8036.0036.0019.2019.202.402.40Harga Sasaran MedianQ4 '20Q4 '20Q1 '21Q1 '21Q2 '21Q2 '21Q3 '21Q3 '21Q4 '21Q4 '21Q1 '22Q1 '22Q2 '22Q2 '22Q3 '22Q3 '22Q4 '22Q4 '22Q1 '23Q1 '23Q2 '23Q2 '23Q3 '23Q3 '23Q4 '23Q4 '23Q1 '24Q1 '24Q2 '24Q2 '24Q3 '24Q3 '24Q4 '24Q4 '24Q1 '25Q1 '25Q2 '25Q2 '25
Julat 52 Minggu
6.99 (-54%) — 17.75 (16%)
Julat Harga Sasaran
15.00 (-1%) — 21.00 (37%)
Tinggi 21.00 (Mizuho, 37.80%) Beli
Median 19.00 (24.67%)
Rendah 15.00 (Goldman Sachs, -1.58%) Pegang
Purata 18.80 (23.36%)
Jumlah 4 Beli, 1 Pegang
Harga Purata @ Panggilan 14.45
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
Needham 09 Apr 2025 20.00 (31.23%) Beli 14.57
03 Apr 2025 20.00 (31.23%) Beli 16.16
HC Wainwright & Co. 03 Apr 2025 19.00 (24.67%) Beli 16.16
26 Feb 2025 19.00 (24.67%) Beli 13.22
Jefferies 11 Mar 2025 19.00 (24.67%) Beli 15.49
Goldman Sachs 27 Feb 2025 15.00 (-1.57%) Pegang 12.80
Mizuho 26 Feb 2025 21.00 (37.80%) Beli 13.22

Tiada data dalam julat masa ini.

  • 3M
Tarikh Jenis Butiran
02 May 2025 Pengumuman Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
17 Apr 2025 Pengumuman Arcutis to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025
10 Apr 2025 Pengumuman Arcutis Announces Chief Financial Officer Transition
04 Apr 2025 Pengumuman Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Apr 2025 Pengumuman Arcutis and Padagis Agree to Stay Patent Lawsuit
27 Mar 2025 Pengumuman Arcutis to Present at the 24th Annual Needham Virtual Healthcare Conference
07 Mar 2025 Pengumuman Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting
05 Mar 2025 Pengumuman Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
28 Feb 2025 Pengumuman Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting
26 Feb 2025 Pengumuman U.S. FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis 
25 Feb 2025 Pengumuman Arcutis Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
24 Feb 2025 Pengumuman Arcutis Announces Publication of Positive Data from INTEGUMENT-PED Trial Evaluating ZORYVE® (roflumilast) Cream 0.05% in Children 2 to 5 Years Old with Mild to Moderate Atopic Dermatitis in Pediatric Dermatology
18 Feb 2025 Pengumuman Arcutis to Present at the TD Cowen 45th Annual Health Care Conference
Papar semua
15.7715.7715.0215.0214.2814.2813.5413.5412.8012.80Apr 23Apr 23Apr 24Apr 24Apr 25Apr 25Apr 28Apr 28Apr 29Apr 29Apr 30Apr 30May 1May 1May 2May 2

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

10010075755050252500RSI (14H)
0.1000.100-0.000-0.000-0.100-0.100-0.200-0.200-0.300-0.300MACD (12, 26, 9)

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda